Characteristics of patients with diabetes related autoantibodies after interferon alpha therapy for chronic hepatitis C infection
| Patient No/sex/age | Mode of infection/genotype of HCV | Date of interferon therapy | Diabetes related autoantibodies | Estimated risk for type 1 diabetes |
| No 1/male/52 y | Unknown/genotype 1 | 8/98–8/99 | IAA, GAD 65 | Moderate |
| No 2 /male/49 y | IV drug use/genotype 1 | 9/98–3/99 | ICA, GAD, IA2 | High |
| No 3/female/48 y | Blood transfusion/genotype 1 | 7/98–7/99 | IAA | Low |
| No 4/male/41 y | Unknown/genotype 3 | 11/98–5/99 | IAA | Low |
ICA, islet cell antibodies; GAD65, autoantiodies to glutamate decarboxylase 65; IA2, autoantibodies to tyrosine phosphatase IA2; IAA, insulin autoantibodies.